Cite
HARVARD Citation
Patel, H. et al. (2023). RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells. Anti-cancer drugs. 34 (4), pp. 519-531. [Online].